

2025 Current Fiscal Year Report: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel

Report Run Date: 07/10/2025 03:40:50 AM

1. Department or Agency		2. Fiscal Year	
Department of Health and Human Services		2025	
3. Committee or Subcommittee		3b. GSA Committee No.	
Disease, Disability, and Injury Prevention and Control Special Emphasis Panel		1910	
4. Is this New Fiscal Year?	5. Current Charter	6. Expected Renewal Date	7. Expected Term Date
No	08/17/2024	08/17/2026	
8a. Was Terminated During Fiscal Year?	8b. Specific Termination Authority	8c. Actual Term Date	
No	E.O. 14217		
9. Agency Recommendation for Next Fiscal Year	10a. Legislation Req to Terminate?	10b. Legislation Pending?	
Terminate	Not Applicable	Not Applicable	
11. Establishment Authority Authorized by Law			
12. Specific Establishment Authority	13. Effective Date	14. Committee Type	14c. Presidential?
42 USC 217a	11/17/1962	Continuing	No
15. Description of Committee Grant Review Committee			
16a. Total Number of Reports	No Reports for this Fiscal Year		
17a. Open	17b. Closed	17c. Partially Closed	Other Activities
0	2	0	0
17d. Total			
2			
Meetings and Dates			
Purpose	Start	End	

To review and evaluate grant applications in response to (SEP) RFA-OH-22-005 Commercial Fishing Occupational Safety Research Cooperative Agreement and RFA-OH-22-006 Commercial Fishing Occupational Safety Training Project Grants. 10/22/2024 - 10/22/2024

To review and evaluate grant applications in response to (SEP) PAR 18-812 NIOSH Member Conflict Review. 10/29/2024 - 10/29/2024

Number of Committee Meetings Listed: 2

	Current Next	
	FY	FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Administrative Costs (FRNs, contractor support, In-person/hybrid/virtual meetings)	\$0.00	\$0.00
18d. Other (all other funds not captured by any other cost category)	\$0.00	\$0.00
18e. Total Costs	\$0.00	\$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

During Fiscal Year (FY) 2024, the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel reviewed 290 applications for grant, contract solicitation and cooperative agreement assistance to fund a broad range of research and to develop programs. Of the 290 grant, contract and cooperative agreement applications, 114 applications were recommended and approved for funding for a total \$75,379,933.

20b. How does the Committee balance its membership?

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel membership represented expertise pertinent to the respective subject areas of each Special Emphasis Panel and included representation from all areas of the public, and academia. Membership was balanced in terms of geographic, demographic, and points of view represented.

20c. How frequent and relevant are the Committee Meetings?

Meetings are held as necessary to review applications and proposals for research projects, grants, and cooperative agreements. During FY 2024, the Special Emphasis Panels met 36 times. This reflects the continuing critical role of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel in CDC's grant and cooperative agreement review process.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

One of the most important methods CDC utilizes to accomplish its mission is through awarding grants. The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel

provides comprehensive and reliable evaluations of application reviews and proposals for research projects, grants and cooperative agreements in the areas of the causes, prevention and control of diseases, disabilities, injuries and impairments of public health significance; exposure to hazardous substances in the environment; health promotion and education; and other related activities that promote health and well-being. Reviews are conducted under the highest ethical standards by including federal and private subject matter experts representing diverse populations and interests assuring that the selection of applications meet program requirements with established criteria and best practices. The integrity of the review process, the ability to award and process grants that are credible, equitable, timely and unbiased and CDC's responsiveness to applicants is facilitated by the Panel.

20e. Why is it necessary to close and/or partially closed committee meetings?

All Special Emphasis Panel meetings were closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The review and discussion of the applications could reveal confidential trade secrets or commercial property such as patentable material and information of a confidential nature, including personal information concerning individuals associated with the applications, the disclosure of which would constitute an unwarranted invasion of personal privacy.

21. Remarks

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP) is a grant review committee and does not generate reports. The members of this Special Emphasis Panel

(SEP) do not have standing appointments and serve on an as needed basis for meetings throughout the fiscal year. Therefore, the Members list reflects meeting dates, not appointment start and end dates. Members generally serve for 1-day meetings and some members are appointed to the SEP multiple times for multiple meetings. The following members were appointed and served on the SEP multiple times for multiple meetings: Ann Backus (11/14/23, 5/14/2024); Antoine Alston (11/14/23, 2/28/2024, 5/14/2024); Grace Sembajwe (10/5/23, 2/26/2024, 2/28/2024); Guohua Li (2/26/2024, 2/28/2024); Hamid Fonooni (2/26/2024, 2/28/2024); Hang Lee (4/9/2024, 4/10/2024); Helaine Alessio (4/9/2024, 4/10/2024); Homero Harari (11/30/23, 2/26/2024); Huiyun (Henry) Xiang (3/26/2024, 6/13/2024), James Lloyd Michener (5/2/2024, 5/15/2024); Janessa M. Graves (2/26/2024, 4/2/2024); Jeffrey C. Woldstad (10/5/23, 5/13/2024); Jun Wang (2/26/2024, 2/28/2024); Karen L. Heaton (2/26/2024, 2/28/2024); Kari L. Babski-Reeves (11/30/23, 5/23/2024); Kitty H. Gelberg (5/13/2024, 5/23/2024); Lavanya Vasudevan (4/9/2024, 4/10/2024); Marie-Anne Rosenberg (2/26/2024, 6/13/2024); Maryann Mason (3/12/2024, 3/26/2024); Matthew Asare (5/7/2024, 5/14/2024); Michael L. Pate (11/14/23, 5/14/2024); Mitchel Rosen (2/26/2024, 2/28/2024); Richard John Webby (4/9/2024, 4/10/2024); Ruiwen Zhang (10/5/23, 2/28/2024); Sang D. Choi (2/28/2024, 5/14/2024); Sarah-Jeanne Salvy (4/11/2024, 5/2/2024); Shane Stephen Que Hee (10/5/23, 11/30/23); Tobili Sam-Yellowe (4/9/2024, 4/10/2024); Traci Byrd (2/26/2024, 5/13/2024); Vijay Golla (2/26/2024, 2/28/2024). There were 36 SEP meetings held and 71 Chairs and co-Chairs served on the panel review meetings.

Designated Federal Officer

Gladys G. Lewellen Director, FACAP and
Committee Management Officer, CDC

Narrative Description

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel shall review applications and proposals for research projects, grants, and cooperative agreements in order to provide advice and guidance to the Secretary, HHS; the Director, Centers for Disease Control and Prevention (CDC), and Administrator, Agency for Toxic Substances and Disease Registry (ATSDR), regarding the concept review, scientific and technical merit of grant and cooperative agreement assistance applications, and contract proposals relating to the causes, prevention, and control of diseases, disabilities, injuries, and impairments of public health significance; exposure to hazardous substances in the environment; health promotion and education; and other related activities that promote health and well-being.

What are the most significant program outcomes associated with this committee?

	Checked if Applies
Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input checked="" type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input checked="" type="checkbox"/>
Implementation of laws or regulatory requirements	<input type="checkbox"/>
Other	<input type="checkbox"/>

Outcome Comments

N/A

What are the cost savings associated with this committee?

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

N/A

What is the approximate Number of recommendations produced by this committee for the life of the committee?

0

Number of Recommendations Comments

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

0%

% of Recommendations Fully Implemented Comments

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

0%

% of Recommendations Partially Implemented Comments

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☐ No ☐ Not Applicable ☒

Agency Feedback Comments

The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations. The agency provides the committee and the public information on award funding.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

N/A

Is the Committee engaged in the review of applications for grants?

Yes

What is the estimated Number of grants reviewed for approval 290

What is the estimated Number of grants recommended for approval 114

What is the estimated Dollar Value of grants recommended for approval \$75,379,933

Grant Review Comments

During fiscal year 2023, the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP) Notice of Funding Opportunity (NOFO) DP24-004 (August 28–31, 2023) was approved for funding of which twenty (20) applications were awarded in the amount of \$19,984,250 and \$121,110 additional contract costs were paid during FY24. Also, NOFO IP23-006 (March 7, 2023) was approved for funding and one (1) application was awarded \$1,000,000 in funding and \$3,270 additional contract costs were paid during FY24. In addition, NOFO CE24-001, Panel A (May 16–17, 2023) was approved for funding and five (5) applications were awarded \$4,249,508 during FY24 and NOFO

CE24-001, Panel B (May 17–18, 2023) was approved for funding and six (6) applications were awarded \$5,041,052 for a total dollar value of grants recommended and additional contract costs in FY24 of \$105,779,123. In addition, NOFO PAR 18-812 convened on October 5, 2023, and three (3) applications/cooperative agreements were reviewed and \$2,500 was requested but unfunded/approved at the time. Also, PS24-039/-042 convened on May 1-2, 2024, and nine (9) applications/cooperative agreements were reviewed and \$3,286 was requested but unfunded/approved at the time. Next, OH24-001 convened on May 13-14, 2024, and two (2) applications/cooperative agreements were reviewed and \$7,250 was requested but unfunded/approved at the time. Also, NOFO PAR 18-812 #2 convened on June 13, 2024, and two (2) applications/cooperative agreements were reviewed and \$1,500 was requested but unfunded/approved at the time. Additionally, OH22-005/-006 #1 convened on November 14, 2023, and four (4) applications/cooperative agreements were reviewed and \$2,231,865 was requested and four (4) approved during FY24. Also, OH22-003 convened on November 30, 2023, and nine (9) applications/cooperative agreements were reviewed and \$691,230 was requested and six (6) approved during FY24. Also, PS24-063 convened on February 22-23, 2024, and nine (9) applications/cooperative agreements were reviewed and \$1,761,174 was requested and five (5) approved during FY24. Also, OH23-003, Panel A convened on February 26-27, 2024, and five (5) applications/cooperative agreements were reviewed and \$3,829,017 was requested and five (5) approved during FY24. Also, OH23-003, Panel B convened on February 28-29, 2024, Panel B, and three (3) applications/cooperative agreements were reviewed and \$2,473,689 was requested and three (3) approved during FY24. Also, CE24-034 convened on February 27-28, 2024, and eleven (11) applications/cooperative agreements were reviewed and \$703,844 was requested and two (2) approved during FY24. In addition, CE24-013 convened on March 12-14, 2024, and twenty-five (25) applications/cooperative agreements were reviewed and \$2,326,997 was requested and three (3) approved during FY24. Next, CE24-029 convened on March 19, 2024, and seven (7) applications/cooperative agreements were reviewed and \$201,433 and one (1) approved during FY24. Also, SEP CE24-012 convened on March 26, 2024, and six (6) applications/cooperative agreements were reviewed and \$1,448,365 was requested and four (4) approved during FY24. In addition, PS24-040 convened on March 28, 2024, and four (4) applications/cooperative agreements were reviewed and \$1,002,798 was requested and one (1) approved during FY24. In addition, CE24-030 convened on April 2, 2024, and eight (8) application/cooperative agreements were reviewed and \$1,245,323. was requested and three (3) approved during FY24. Also, GH24-033 convened on April 9, 2024, and ten (10) applications/cooperative agreements were reviewed and \$610,493 and seven (7) approved during FY24. In addition, GH21-001/-003/GH24-033 convened on April 10, 2024, and twelve (12) applications/cooperative agreements were reviewed and

\$8,665,754 and five (5) approved during FY24. Next, DP24-031 convened April 10, 2024, and three (3) applications/cooperative agreements were reviewed and \$840,802 and one (1) approved during FY24. Also, DP24-081 convened on April 11, 2024, and eleven (11) applications/cooperative agreements were reviewed and \$3,216,996 was requested and five (5) approved during FY24. Also, TS24-010 convened on April 9, 2024, and three (3) applications/cooperative agreements were reviewed and \$850,333 and two (2) approved during FY24. In addition, CE22-003 convened on April 11, 2024, and four (4) applications/cooperative agreements were reviewed and \$165,043 was requested and four (4) approved during FY24. Also, IP24-046 convened on April 11, 2024, and two (2) applications/cooperative agreements were reviewed and \$4,502,846 and one (1) approved during FY24. Also, IP24-045 convened on April 25-26, 2024, and twenty-eight (28) applications/cooperative agreements were reviewed and \$14,170,789 was requested and three (3) approved during FY24. Additionally, SIP24-001/-002/-005 convened on April 30, 2024, and twelve (12) applications/cooperative agreements were reviewed and \$628,138 was requested and two (2) approved during FY24. In addition, SIP24-003 convened on May 1, 2024, and eleven (11) applications/cooperative agreements were reviewed and \$3,097,489 was requested and nine (9) approved during FY24. Next, SIP24-006/-007/-010 convened on May 2, 2024, and seven (7) applications/cooperative agreements were reviewed and \$20,711 was requested but unfunded/approved during fiscal year 2024. In addition, SIP24-011/-013 convened on May 7, 2024, and four (4) applications/cooperative agreements were reviewed and \$513,066 was requested and one (1) approved during FY24. Also, SIP24-004 convened on May 8, 2024, and three (3) applications/cooperative agreements were reviewed and \$361,958 was requested and one (1) approved during FY24. Also, SIP24-008 convened on May 9, 2024, and four (4) applications/cooperative agreements were reviewed and \$963,071 was requested and three (3) approved during FY24. Also, OH24-001 convened on May 13-14, 2024, and two (2) applications/cooperative agreements were reviewed and \$4,987,418 were requested and one (1) approved during FY24. Next, SIP24-012 convened on May 14, 2024, and five (5) applications/cooperative agreements were reviewed and \$1,814,098 was requested and five (5) approved during FY24. In addition, OH22-005/-006 #2 convened on May 14, 2024, and five (5) applications/cooperative agreements were reviewed and \$690,480 was requested and one (1) approved during FY24. Next, SIP24-009 convened on May 15, 2024, and seven (7) applications/cooperative agreements were reviewed and \$816,383 was requested and three (3) approved during FY24. Next, IP24-017/-081 convened on May 17, 2024, and two (2) applications/cooperative agreements were reviewed and \$3,001,911 was requested and one (1) approved during FY24. Also, DP24-138 convened on May 21, 2024, and six (6) applications/cooperative agreements were reviewed and \$1,473,369 was requested and three (3) approved during FY24. In addition, OH22-002 convened on May 23, 2024, eight (8) applications/cooperative agreements were reviewed

and \$548,639 was requested and two (2) approved during FY24. Finally, PAR 20-280/OH24-002/-003/-004 convened on May 28-30, 2024, and thirty-six (36) applications/cooperative agreements were reviewed and \$4,145,459 was requested and fifteen (15) approved during FY24.

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input type="checkbox"/>
Other	<input type="checkbox"/>

Access Comments

<https://www.cdc.gov/faca/committees/ddipcsep/index.html>